NCT03153579View on ClinicalTrials.gov

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions
PatientsAnxiety Disorders
Interventions
DRUG

LSD

"Lysergic Acid Diethylamide~200ug per os, single dose"

DRUG

Placebo

Capsules containing mannitol looking identical to LSD

Trial Locations (2)

4056

University Hospital Basel, Basel

4500

Private Practice P.Gasser, Solothurn

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03153579 - LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders | Biotech Hunter | Biotech Hunter